Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046228 · ClinicalTrials.gov registry record · Phase 3
A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
A Phase 3 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,461
- Enrollment target
NCT00046228 is a Phase 3 study that has completed, run by Centocor. The registered enrollment target is 2,461 participants.
The verdict
NCT00046228, a Phase 3 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,461 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood flowing past the clot), is safe and effective in the treatment of heart attacks compared to only abciximab given during coronary intervention.
Interventions
- DRUG abciximab placebo; reteplase placebo, abciximab, abciximab
- DRUG Abciximab; reteplase; abciximab placebo; abciximab
- DRUG abciximab; reteplase placebo; abciximab placebo; abciximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,461 participants |
| Start Date | 2002-08 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00046228
The ClinicalTrials.gov registry entry for NCT00046228 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,461 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which abciximab placebo; reteplase placebo, abciximab, abciximab is the first listed.
NCT00046228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00046228 about?
NCT00046228 is a clinical study titled "A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)". The purpose of this study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood flowing past the clot), is safe and effective in the treatment of heart ...
What is the current status of trial NCT00046228?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,461 participants. The study started on 2002-08. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00046228?
The interventions under investigation include: abciximab placebo; reteplase placebo, abciximab, abciximab (DRUG), Abciximab; reteplase; abciximab placebo; abciximab (DRUG), abciximab; reteplase placebo; abciximab placebo; abciximab (DRUG).
Who is sponsoring clinical trial NCT00046228?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.